A Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab and With Standard Chemotherapy in Patients With Advanced Lung Cancer
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 119
- 试验地点
- 1
- 主要终点
- Incidence of SAEs
研究概览
简要总结
This is an open-label phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of JS004 injection combined with toripalimab and with or without standard chemotherapy in patients with advanced lung cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects are eligible for the study if they meet all of the following criteria:
- •Sign the informed consent form voluntarily;
- •Males or females ≥18 years at the time of signing the informed consent;
- •Expected survival ≥3 months;
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 ;
- •Pathologically confirmed locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), which is currently not suitable for local treatment such as radical surgery or radiotherapy; For subjects with non-squamous carcinoma, there is no EGFR sensitive mutation or ALK fusion; for subjects with squamous carcinoma, genetic testing is not mandatory
- •Pathologically confirmed extensive-stage small cell lung cancer (ES-SCLC, according to the Veterans Administration Lung Study Group (VALG) staging), previously received no systemic anti-tumor therapy for ES-SCLC (Cohort 5); Subjects with limited-stage SCLC who have previously received systemic anti-tumor therapy cannot be enrolled;
- •The subject has at least one measurable lesion as a target lesion (RECIST v1.1 criteria,);
- •The subject agrees to provide tumor tissue samples ;
- •The subject has good organ function as indicated by screening laboratory results:
- •Males of reproductive potential or females of childbearing potential must use effective contraceptive methods during the trial and continue for 6 months after the end of treatment;
- •The subject has good compliance and cooperates with the follow-up.
排除标准
- •Subjects who met any of the following criteria will be excluded from the study:
- •For the third line and second line populations with advanced lung squamous carcinoma (Cohorts 1 and 2), subjects who have received systemic anti-tumor therapy within 3 weeks before the first dose of study drug, including: chemotherapy, targeted therapy, anti-vascular drug therapy, biological therapy, immunotherapy, radiotherapy or other treatments with investigational products
- •Any adverse reactions caused by previous treatments have not recovered to CTCAE (Version 5.0) Grade 1 or below ;
- •Symptomatic metastases to central nervous system.;
- •Subjects with poorly controlled tumor-related pain who require analgesic treatment must receive the treatment at a stable dose before participating in the study;
- •Hydrothorax or ascites or pericardial effusion with clinical symptoms or unstable condition after symptomatic treatment;
- •Subjects previously discontinued treatment due to PD-1/PD-L1 inhibitor toxicity;
- •Known history of severe allergic reactions to JS004 or toripalimab and its components, scheduled chemotherapeutic drugs and their components;
- •Known active or suspected autoimmune diseases, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease;
- •History of interstitial lung disease or drug-induced interstitial lung disease or pulmonitis;
- •Received systemic corticosteroids (prednisone >10 mg/day or equivalent) or other immunosuppressive drugs within 14 days before the first study dose;
- •Subjects with a past history of immunodeficiency, including those with other acquired or congenital immunodeficiency diseases, or with a history of organ transplantation, or have received allogeneic hematopoietic stem cell transplantation or solid organ transplantation;
- •Had received live vaccines within 4 weeks before the first study dose;
- •Any major surgical procedure within 4 weeks before the first study dose. Planned major surgical procedure to be performed within 30 days after the first dose , or not fully recovered from the previous surgery;
- •Suffering from severe cardiovascular and cerebrovascular diseases;
- •Subjects with uncontrolled or serious underlying diseases, including but not limited to active infection requiring systemic antibiotic treatment;
- •Positive human immunodeficiency virus (HIV) antibody test, active hepatitis B or C;
- •Known active Pulmonary tuberculosis (TB)..
- •Any active malignancy other than the disease under study within the past 2 years, except for malignancies that can be expected to be cured after treatment;
- •Subjects who have a history of psychotropic drug abuse and are unable to withdraw or have mental disorder;
- •Pregnant or breastfeeding woman;
- •Other severe, acute or chronic medical or psychiatric disorders or laboratory abnormalities that, at the discretion of the investigator, may increase the risk associated with study participation or may interfere with the interpretation of study results.
研究组 & 干预措施
Cohort 1
NSCLC-squamous carcinoma third line;JS004 200mg + JS001 240mg Q3w, maintained until disease progression
干预措施: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection (Biological)
Cohort 1
NSCLC-squamous carcinoma third line;JS004 200mg + JS001 240mg Q3w, maintained until disease progression
干预措施: Toripalimab (Biological)
Cohort 2
NSCLC-squamous carcinoma second line;JS004 200mg + JS001 240 mg + docetaxel Q3w, maintained until disease progression
干预措施: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection (Biological)
Cohort 2
NSCLC-squamous carcinoma second line;JS004 200mg + JS001 240 mg + docetaxel Q3w, maintained until disease progression
干预措施: Toripalimab (Biological)
Cohort 2
NSCLC-squamous carcinoma second line;JS004 200mg + JS001 240 mg + docetaxel Q3w, maintained until disease progression
干预措施: Docetaxel (Drug)
Cohort 3
NSCLC-non-squamous carcinoma first line;JS004 200mg + JS001 240 mg + pemetrexed + carboplatin/cisplatin Q3w, for 4 cycles;JS004 200mg + JS001 240 mg + pemetrexed, maintained until disease progression
干预措施: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection (Biological)
Cohort 3
NSCLC-non-squamous carcinoma first line;JS004 200mg + JS001 240 mg + pemetrexed + carboplatin/cisplatin Q3w, for 4 cycles;JS004 200mg + JS001 240 mg + pemetrexed, maintained until disease progression
干预措施: Toripalimab (Biological)
Cohort 3
NSCLC-non-squamous carcinoma first line;JS004 200mg + JS001 240 mg + pemetrexed + carboplatin/cisplatin Q3w, for 4 cycles;JS004 200mg + JS001 240 mg + pemetrexed, maintained until disease progression
干预措施: Pemetrexed (Drug)
Cohort 3
NSCLC-non-squamous carcinoma first line;JS004 200mg + JS001 240 mg + pemetrexed + carboplatin/cisplatin Q3w, for 4 cycles;JS004 200mg + JS001 240 mg + pemetrexed, maintained until disease progression
干预措施: Cisplatin (Drug)
Cohort 3
NSCLC-non-squamous carcinoma first line;JS004 200mg + JS001 240 mg + pemetrexed + carboplatin/cisplatin Q3w, for 4 cycles;JS004 200mg + JS001 240 mg + pemetrexed, maintained until disease progression
干预措施: Carboplatin (Drug)
Cohort 4
NSCLC-squamous cell carcinoma first line;JS004 200mg + JS001 240 mg + paclitaxel + carboplatin Q3w, for 4 cycles; JS004 200mg + JS001 240 mg, maintained until disease progression
干预措施: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection (Biological)
Cohort 4
NSCLC-squamous cell carcinoma first line;JS004 200mg + JS001 240 mg + paclitaxel + carboplatin Q3w, for 4 cycles; JS004 200mg + JS001 240 mg, maintained until disease progression
干预措施: Toripalimab (Biological)
Cohort 4
NSCLC-squamous cell carcinoma first line;JS004 200mg + JS001 240 mg + paclitaxel + carboplatin Q3w, for 4 cycles; JS004 200mg + JS001 240 mg, maintained until disease progression
干预措施: Carboplatin (Drug)
Cohort 4
NSCLC-squamous cell carcinoma first line;JS004 200mg + JS001 240 mg + paclitaxel + carboplatin Q3w, for 4 cycles; JS004 200mg + JS001 240 mg, maintained until disease progression
干预措施: Paclitaxel (Drug)
Cohort 5
SCLC first line;JS004 200mg + JS001 240 mg + etoposide + carboplatin/cisplatin Q3w, for 4 cycles; JS004 200mg + JS001 240 mg, maintained until disease progression
干预措施: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection (Biological)
Cohort 5
SCLC first line;JS004 200mg + JS001 240 mg + etoposide + carboplatin/cisplatin Q3w, for 4 cycles; JS004 200mg + JS001 240 mg, maintained until disease progression
干预措施: Toripalimab (Biological)
Cohort 5
SCLC first line;JS004 200mg + JS001 240 mg + etoposide + carboplatin/cisplatin Q3w, for 4 cycles; JS004 200mg + JS001 240 mg, maintained until disease progression
干预措施: Cisplatin (Drug)
Cohort 5
SCLC first line;JS004 200mg + JS001 240 mg + etoposide + carboplatin/cisplatin Q3w, for 4 cycles; JS004 200mg + JS001 240 mg, maintained until disease progression
干预措施: Carboplatin (Drug)
Cohort 5
SCLC first line;JS004 200mg + JS001 240 mg + etoposide + carboplatin/cisplatin Q3w, for 4 cycles; JS004 200mg + JS001 240 mg, maintained until disease progression
干预措施: Etoposide (Drug)
结局指标
主要结局
Incidence of SAEs
时间窗: 2 years
Incidence of serious adverse events (SAEs)
Incidence of adverse events (AEs)
时间窗: 2 years
Incidence of adverse events (AEs)
ORR
时间窗: 2 years
Efficacy endpoint: objective response rate (ORR) based on RECIST v1.1 criteria
Incidence of irAEs
时间窗: 2 years
Incidence of immune-related adverse events (irAEs)
次要结局
- titer of ADA(2 years)
- time to response (TTR)(2 years)
- PFS(2 years)
- 1-year OS rate(1 year)
- incidence of ADA(2 years)
- incidence of Nab(2 years)
- DOR(2 years)
- titer of Nab(2 years)
- DCR(2 years)
- OS(2 years)
- Drug concentration in plasma(2 years)